Investigative Report on Chinese Tigercycline Markets, 2016-2020 & 2021-2025: An Intravenously Administered Broad-Spectrum Cyclic Glycyl Peptide Antibiotic – ResearchAndMarkets.com

0

DUBLIN–(BUSINESS WIRE)–The “China Tigercycline Market Investigation Report 2021-2025” report has been added to from ResearchAndMarkets.com offer.

Tigercycline is a broad-spectrum cyclic glycyl peptide antibiotic administered intravenously. Tigercycline is approved for complicated infections of the skin and skin appendages or complicated intra-abdominal infections in patients 18 years of age and older.

These infections include complicated appendicitis, burn, intra-abdominal abscess, deep soft tissue infection, and ulcer infection.

Tigercycline was developed by Wyeth Corporation of the United States and was listed in China under the trade name TYGACIL in 2011. Subsequently, some generic drugs from local Chinese companies were listed. In 2020, tigecycline was included in class B medical insurance in China, and there are several manufacturers in China’s tigecycline market.

According to the market research, the sales value of tigecycline in the Chinese market increased year-on-year at a compound annual growth rate of 43.45% from 2016 to 2019.

Due to the impact of COVID-19 on the entire diagnostic and treatment departments of Chinese hospitals, the sales value of tigecycline in the Chinese market decreased to CNY 885 million in 2020 and the CAGR of the value of sales of tigecycline from 2016 to 2020 is 28.64%.

The analyst expects the sales value of tigecycline in the Chinese market to experience restorative growth from 2016 to 2020 with the relief of COVID-19. According to the latest set of data released by the World Health Organization, 700,000 people worldwide die each year due to infection with “super bacteria”, and 230,000 newborn babies die prematurely because of it. .

It can be estimated that by 2050 the number of deaths could exceed 10 million. Therefore, the sales value and sales volume of tigecycline against “super bacteria” such as methicillin-resistant Staphylococcus aureus (MRSA) will continue to increase.

By the first half of 2021, the new indication of tigecycline in the Chinese community-acquired and hospital-acquired pneumonia market is under review. It can be expected that with the increase of new indications in the future, the sales value and sales volume of tigecycline may increase.

Topics Covered:

  • The impact of COVID-19 on the Chinese tigecycline market

  • Sales value of tigecycline in China 2016-2020

  • Competitive landscape of Chinese tigecycline market

  • tigecycline price in china

  • Tigercycline Price in China by Regions and Manufacturers

  • Analysis of factors affecting the development of the Chinese tigecycline market

  • China tigecycline market outlook from 2021 to 2025

Main topics covered:

1 Relevant concepts of tigecycline

1.1 Indications for tigecycline

1.2 Tigercycline Development in China

1.3 Government approval of tigecycline in China

1.4 The impact of COVID-19 on the sales of tigecycline in China

2 China Tigercycline Sales, 2016-2020

2.1 Tigercycline Sales Value

2.1.1 Overall sales value

2.1.2 Sales Value by Region

2.2 Tigercycline Sales Volume

2.2.1 Overall Sales Volume

2.2.2 Sales Volume by Region

2.3 China Tigercycline Sales by Dosage Form, 2016-2020

2.3.1 Injection

2.3.2 Analysis of other dosage forms

3 Analysis of the key manufacturers of tigecycline in China, 2016-2020

3.1 Major Manufacturers Market Share Analysis of Tigercycline

3.1.1 Market Share Survey by Sales Value

3.1.2 Market Share Survey by Sales Volume

3.2 Pfizer SA

3.2.1 Company profile

3.2.2 China TYGACIL (Tigecycline by Pfizer Ltd) Sales

3.3 Jiangsu Hansoh Pharmaceutical Group Co., Ltd.

3.3.1 Company Profile

3.3.2 Zhetan (Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Tigercycline) Sales in China

3.4 Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

3.4.1 Company Profile

3.4.2 China Tianjie (Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Tigercycline) Sales

3.5 Zhejiang Hisun Pharmaceutical Co., Ltd.

3.5.1 Business Profile

3.5.2 Hisun Liliang (Zhejiang Hisun Pharmaceutical Co., Ltd. Tigercycline) Sales in China

3.6 Jiangsu Osaikang Pharmaceutical Co., Ltd.

3.6.1 Company Profile

3.6.2 China Aotijia (Tigecycline by Jiangsu Osaikang Pharmaceutical Co., Ltd.) Sales

4 tigecycline price for different manufacturers in China, 2020-2021

4.1 Pfizer Ltd (TYGACIL)

4.2 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. (Zhetan)

4.3 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (Tianjie)

4.4 Zhejiang Hisun Pharmaceutical Co., Ltd. (Hisun Liliang)

4.5 Jiangsu Osaikang Pharmaceutical Co., Ltd. (Aotijia)

5 China Tigercycline Drug Market Outlook, 2021-2025

5.1 Influencing factors on the development of the China tigecycline market

5.1.1 The impact of COVID-19 on the Chinese tigecycline market

5.1.2 Market Drivers and Opportunities

5.1.3 Market Threats and Challenges

5.2 Market Size Forecast

5.3 Market Trend Forecast

Companies cited

  • Pfizer Ltd (TYGACIL)

  • Jiangsu Hansoh Pharmaceutical Group Co., Ltd. (Zhetan)

  • Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (Tianjie)

  • Zhejiang Hisun Pharmaceutical Co., Ltd. (Hisun Liliang)

  • Jiangsu Osaikang Pharmaceutical Co., Ltd. (Aotijia)

For more information on this report, visit https://www.researchandmarkets.com/r/6fb5l2

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, top companies, new products and the latest trends.

contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Officer

[email protected]
For EST business hours, call 1-917-300-0470

For US/CAN call toll free 1-800-526-8630

For GMT office hours call +353-1-416-8900

source link

Content is from Business Wire. Headlines of Today Media is not responsible for the content provided or any links to such content. Headlines of Today Media is not responsible for the accuracy, timeliness or quality of the content.

Share.

Comments are closed.